Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L)

  1. Garcia Campelo, M.R.
  2. Lin, H.M.
  3. Zhu, Y.
  4. Pérol, M.
  5. Jahanzeb, M.
  6. Popat, S.
  7. Zhang, P.
  8. Camidge, D.R.
Revista:
Lung Cancer

ISSN: 1872-8332,  0169-5002

Ano de publicación: 2021

Volume: 155

Páxinas: 68-77

Tipo: Artigo

DOI: 10.1016/J.LUNGCAN.2021.03.005 GOOGLE SCHOLAR lock_openAcceso aberto editor
Fonte de datos: Scopus